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Magnesium is the second most abundant intracellular cation with many control
and regulatory functions. It regulates energy production and utilization and
modulates activity of membrane ionic channels.
Magnesium has direct control effects on cardiac myocyte ion channels making it
useful in certain arrhythmias. Calcium is responsible for pacemaker excitation
and for excitation-contraction coupling in myocytes but increased intracellular
calcium produces early and late afterdepolarisations initiating arrhythmias.
Magnesium regulates calcium channel activity preventing raised intracellular
levels. Potassium channel activity is enhanced by magnesium hyperpolarizing
the cell reducing arrhythmia generation.
Magnesium is effective against long QT Torsade de Pointes. In rapid atrial
fibrillation magnesium produces rate control slowing AV nodal conduction.
Magnesium prevents digitalis toxicity due to associated hypomagnesemia.
Magnesium;Arrhythmias; Ion channels;Action potential; Ischemia
Magnesium as in intracellular ion serves over 300 intracellular metabolic and
regulatory functions. Within the cardiac system it is responsible for modulating
mitochondrial metabolism, various membrane receptors and ion channels. It has
both direct and indirect effects on the cardiac action potential which suggests its
usefulness as an antiarrhythmic agent.
This article will explore the normal function of intracellular magnesium in cardiac
cells in relation to electrophysiology. The role magnesium has on the various ion
channels responsible for the myocyte action potential and in arrhythmogenesis
will be reviewed. The use of intravenous magnesium in managing these
arrhythmias especially Torsades de pointes, atrial fibrillation and digitalis toxicity
will be discussed using latest evidence from literature.
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2. METHOD
3. MAGNESIUM IN CARDIAC CELLULAR PHYSIOLOGY
a. Magnesium as cofactor for many intracellular enzymes.
b. Role of magnesium in effecting cardiac cellular ionic activity
Although there are some small studies on magnesium's use in specific
arrhythmia management none explore the broader use in cardiology. Therefore
this literature review seeks to explore the current evidence for magnesium use in
arrhythmia management and in its effects on cellular biochemistry which may
highlight future possible research opportunities in clinical practice.
The following databases were searched for relevant texts: Science Direct,
Ebsohost (Medline), Proquest, Oxford University Press and Pubmed. The key
words used were: Magnesium, arrhythmias, antiarrhythmic, atrial fibrillation,
Torsades de Pointes, digoxin and specific texts on magnesium in biochemistry
for effects on each of the specific ion channels.All studies using both animals and
humans were included. Review article reference lists were searched for further
relevant texts.
Magnesium is the second most abundant intracellular metal cation (positively
charged ions) with concentrations between 0.4 – 1 mmol/L (Mubagwa ,
2007). The concentration gradient of magnesium is about 10 mM intracellular to
1 mM extracellular (Wolf , 2003). It is associated with multiple intracellular
functions: Transmembrane channel modulation, cellular energy production,
synthesis of proteins and nucleic acids and enzyme activity (Saris 2000).
The most noted ionic function of magnesium is as cofactor on the enzyme Na -K
ATPase (Saris , 2000). This plays a role in activation and function of the Na -
K pump - an important part of repolarisation in phase 4 of the action potential.
ATP binds to sites on the ion channels in the presence of Mg .ATP is hydrolyzed
to ADP with the release of P providing energy to pump Na against the
concentration gradient (Lodish , 1995). Decreased intracellular sodium
raises the concentration gradient across the cell membrane, providing the drive
for the Na -Ca exchanger. This reduces intracellular [Ca ] (Carmeliet, 1999).
Magnesium is also responsible for activating thiamine into thiamine
pyrophosphate, modulating cellular metabolism of glucose in the production of
intracellular energy substrate ATP (Johnson, 2001). Magnesium modulates the
oxidant-antioxidant status, increasing antioxidant defense (Wolf , 2003).
Magnesium alters ions channels via four mechanisms: pore block, allosteric
effects, modulation of enzymes or G-proteins and interacting with surface
charges (Mubagwa et al, 2007). Pore block is voltage dependant and may
produce altered direction of the current flow at positive voltages. Allosteric
















(Meissner, 2004). Calmodulin is one of the regulators of Calcium induced
Calcium release (CICR) from the SR via Ryanodine receptors (Meissner, 2004).
After depolarization Ca is either transported into the SR or out of the cell via the
Na Ca exchanger (Klabunde, 2005). Decreasing the intracellular calcium influx
has negative chronotropy (on pacemaker cells), ionotropy (on myocytes) and
dromotropy (on theAV node) (Klabunde, 2005).
Increased intracellular Ca is linked to early (EAD) and delayed
afterdepolarisations (DAD) thus increasing the risk of arrhythmogenesis
(Aomine , 1999). EAD are thought to arise from spontaneous release of Ca
from the SR and inward flow of Na Ca channels. The current is uniform across
the cell membrane (Boyden & ter Keurs, 2005). These abnormal currents are
seen more when the Action Potential is prolonged. This can result from
hypokalemia, hypomagnesemia and bradycardia (Akar & Tomaselli, 2004).
DADs are propagated by transient spontaneous Ca inflow in a focus within the
cell – the so called Ca spike. This focus activates local ryanodine receptors and
sets up a Ca wave across the cell. If the cell Ca concentration is high this may
cause threshold to be reached with subsequent depolarization (Boyden & ter
Keurs, 2005)
L-type Ca channels studied in rats showed suppression by magnesium at
physiological levels increasing especially in the upper range (Wang, Tashiro &
Berlin, 2003; Shorofsky & Balke, 2001). This suppression can be in two forms:
physiological with magnesium entering and slowing conduction through the
channel; or by increased extracellular concentration thus altering membrane
polarization (Delva, 2003). Increased MgATP on the other hand has been linked
to greater Ca channel opening and longer action potential duration (Shorofsky
& Balke, 2001)
Both Magnesium and calmodulin block the CICR at higher intracellular Ca
levels. Mg competes for the Ca binding site thus relying on high intracellular
levels to achieve the block (Meissner, 2004). L-type Ca currents conducted
through the AV node can be slowed using magnesium or Calcium channel
blockers (Shorofsky & Balke, 2001 Brette , 2006). Thus potentially in
hypomagnesaemia the negative chronotropic effect of magnesium is decreased
predisposing to conduction of tachyarrhythmias. This mechanism may be
important in rapid Atrial Fibrillation (Shorofsky & Balke, 2001; Davey & Teubner,
2005). Magnesium is therefore useful to slow AV conduction in all
supraventricular tachyarrhythmias. [See 4) below].
These are found primarily in nodal tissues (Mubagwa , 2007). They are
thought to play a role in spontaneous depolarization and thus pacemaker
function within the SA and AV nodal tissues (Klabunde, 2005). These channels
are not found in human atrial or ventricular tissues (Perez-Reyes, 2003). The
expression of T type channels is highest in neonatal hearts of all species

















ii. T type Calcium channels
;
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Smaller animal species also have greater expression of these channels
(Vassort, Talavera & Alvarez, 2006) possibly due to the faster heart rates
required. The activity of these channels is most pronounced at low voltage levels
(activation around -50mV with peak around -30 to -20mV) (Vassort, Talavera &
Alvarez, 2006). The T type current is a small burst Ca spike theorized to activate
Na -Ca exchanger currents to bring the cell to threshold (Vassort, Talavera &
Alvarez, 2006).
Their expression increases early in certain cardiac conditions like heart failure
(Perez-Reyes, 2003; Vassort, Talavera & Alvarez, 2006). Their numbers
increase with exposure to increased aldosterone resulting in increased heart
rate and arrhythmias. This may result in EAD and DADs propagation (Vassort,
Talavera &Alvarez, 2006)
Spironolactone is an aldosterone antagonist and is shown to prevent
magnesium loss in heart failure. This was associated with fewer arrhythmias and
slower resting heart rates (Gao , 2007). Physiological levels of Mg were
found to produce a moderate block of this current. This block had greater
significance at more negative voltages (Serrano , 2000). Blocking the T Type
channel current may reduce rate by slowing spontaneous depolarization.
I channels are found in greater numbers in atrial and ventricular contractile cells
and ventricular conducting tissue than in the nodal cells (Mubagwa , 2007).
During phase 3 of the action potential I outward K currents are responsible for
late repolarisation and maintain the resting membrane potential in phase 4 [see
Figure 2] (Mubagwa , 2007). During phase 2 of the action potential there is a
cross- over period of inward current caused by Mg (Rees, 1996) or intracellular
amines spermine and spermadine (Lopatin & Nichols, 2001). This inward current
maintains the plateau and with Ca lengthens the action potential (Lopatin &
Nichols, 2001). This is more pronounced in ventricular than atrial tissue (Lopatin
& Nichols, 2001).
The outward current is decreased by magnesium deficiency thus precipitating a
less negative resting membrane potential (Delva, 2003). This may be due to
upregulation by PKA (cAMP regulated Protein Kinase) which needs MgATP or
free Mg (Lopatin & Nichols, 2001). This may predispose to automaticity with


















Adapted from Klabunde, R.E. Cardiovascular Pharmacology Concepts
v. Other K channels
KATP channels are sensitive to MgATP / MgADP ratios and open during times of
hypoxia causing K+ efflux and preventing Ca2+ accumulation in the cell (Alekseev
et al, 2005). This serves a protective function as Ca2+ buildup can precipitate
apoptosis (Wolf et al, 2003). Magnesium exhibits open channel block creating a
weak inward rectification of the KATP channel (Tamargo et al, 2004; Mubagwa et
al, 2007). Magnesium increases the inhibiting effect of ATP on the outward
currents of KATP.
KAch channels are indirectly activated by magnesium through activation of the G-
Protein on stimulation of Muscarinic or Adenosine receptors (Mubagwa et al,
2007). These channels are found mainly in SA and AV nodal tissue and purkinje
cells in the ventricles (Mubagwa et al, 2007).
4. ISCHEAMIA AND ARRHYTHMIA GENERATION
Ischeamia triggers a chain reaction of intracellular metabolic changes affecting
the structure of ion channels, reducing ATP production and activating increased
formation of oxygen free radicals (Carmeliet, 1999). During hypoxia the cell
begins conserving energy favouring production of lactate. Radicals inhibit Na+
and K+ currents, block the Na+Ca2+ exchanger, Na+ +K ATPase pumps and cause
Ca2+ leak currents making the cell sensitive to Ca2+ overload (Carmeliet, 1999).
This Ca2+ sensitivity includes spontaneous release of Ca2+ from the SR
producing DAD triggering arrhythmias (Shorofsky & Balke, 2001). Failure of the
ATP Ca2+ pump to shift cytosolic Ca2+ into the SR may cause Ca2+ overload
(Boyden & ter Keurs, 2005). This may be a primary mechanism in abnormal
automaticity related arrhythmias (Boyden & ter Keurs, 2005). These currents may
also initiate DAD and EAD triggered activity (Akar & Tomaselli, 2004).
KATP channels activated by either ATP depletion or free radicals cause K
+ outflow
from the cell producing a cellular protective effect (Alekseev et al, 2005).
Figure 3
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Repeated exposure to mild hypoxia produces ischaemic preconditioning. This
response enables the cell to survive prolonged periods of ischeamia (Tamargo
, 2004). Ischaemia produces two stages with distinct electropathological
patterns (Carmeliet, 1999). In the first stage action potential velocity and
amplitude are decreased with a prolonged plateau. EAD and DAD are noted with
prolonged phase 3 repolarisation, shortened absolute and lengthened relative
refractory periods (Carmeliet, 1999 Shorofsky & Balke, 2001). In stage two the
cell depolarizes and exhibits short action potentials, finally hyperpolarizing and
developing irreversible contracture (Carmeliet, 1999).
Hypomagnesaemia has been linked to enhanced 'automaticity and triggered
mechanism' (Gao , 2007) Automaticity is the ability of cells to spontaneously
depolarize to threshold level producing action potential (Akar & Tomaselli, 2004).
Triggered mechanism (DAD or EAD) have previously been discussed (see 3)
above). The third and most common mechanism of arrhythmia is reentry where
propagation occurs around an inexcitable obstacle. The circuit demonstrates a
unidirectional block and slow conduction to allow recovery before the impulse
conducts round again (Akar & Tomaselli, 2004).
Increased Intracellular Mg (measured in erythrocytes) reduced the risk of
premature ventricular ectopics, atrial fibrillation and tachycardia while slowing
heart rates (Gao , 2007). There was no correlation with plasma magnesium
levels to reduced arrhythmia risk (Gao , 2007).Aomine (1999) found that
increasing extracellular magnesium to 10 mM (normal about 1mM) in rat
papillary muscles and guinea pig ventricular cells demonstrated a complete
block of DAD, EAD and triggered activity. Magnesium has been trialed in
reentrant Supraventricular Tachycardias with mixed success (Delva, 2003). The
mechanism being linked to its ability to slowAV conduction (see 3)c)i) above).
TdP can be as a result of drug effects, electrolyte deficiencies or congenital long
QT syndrome (Gowda , 2004 Gupta , 2007). Long QT syndrome is a
primary cause of TdP (Gupta , 2007). Blocking the I current leads to delayed
repolarisation and lengthened QT interval (Gowda , 2004). EAD and
heterogeneous refractoriness may lead to unidirectional block, re-entry circuit
and onset TdP (Gupta , 2007 Akar & Tomaselli, 2004). TdP may be self-
limiting or may degenerate into VF, which is a major safety concern of any drug
which prolongs QT interval (certain antibiotics, second generation
antihistamines, antiarrhythmics and antipyschotics) (Gowda , 2004).
Verduyn (1997) demonstrated significant shortening of the QT, reduced or
suppressed EAD and suppressed ectopic beats in dogs using magnesium IV
infusion. 10 mM Magnesium added to the solution completely abolished EAD
and DAD in Guinea Pig ventricular cells (Aomine , 1999). Magnesium is only
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5. MAGNESIUM AND ARRHYTHMIAS







studies looking at the efficacy of magnesium in TdP management but it appears
safe to use in conjunction with other therapies (ILCOR, 2005).
Atrial fibrillation is a common arrhythmia with clinically significance. In 60 – 70%
of patients it may be associated with rapid ventricular response which requires
rate control (Khan , 2004). Fast ventricular rates limit diastolic filling time thus
decreasing stroke volume and so reducing cardiac output (Khan , 2004).
This rapid ventricular rate may lead to left ventricular failure if not managed
(Davey & Teubner, 2005). The primary goal of rapid AF management is rate
control as cardioversion to normal sinus rhythm without anticoagulation is
associated with thromboembolic risk (ILCOR, 2005).
Magnesium is one of the drugs noted for rate control of rapid atrial fibrillation
(ILCOR, 2005). Mg decreases AV nodal transmission thus helping to slow the
rapidAF (Davey & Teubner, 2005).
Onalan et al (2007) conducted a meta-analysis of 8 low powered randomised
control trials of magnesium used in atrial fibrillation (double blind and non blinded
studies). In a total patient number of 303 (154 Mg and 149 control) the
effectiveness was statistically significant for rate control (OR 1.96, 95% CI 1.24
to 3.08) (Onalan , 2007). Magnesium also demonstrated rhythm control (OR,
1.60, 95% CI 1.07 to 2.39) (Onalan , 2007) which would not be the initial
result desired in prolonged AF (greater than 48 hours). The study by Davey &
Teubner (2005) contributed the largest patient cohort to the meta-analysis
(46.59%) (Onalan , 2007).
Although Davey and Teubner (2005) found a 31% increase in rate control (pulse
below 100 bpm) in the study group compared to placebo (RR 1.89; 95% CI 1.38
to 2.59; P<.0001) magnesium was used in conjunction with other
antiarrhythmics so the effect cannot be directly attributed to magnesium. A
comparison of magnesium to diltiazem in paroxysmalAF showed similar efficacy
with a tendency for magnesium to more consistently restore sinus rhythm by 6
hours (P<0.001) (Chiladakis , 2001).









c. Digitalis toxicity induced arrhythmias
Digitalis works by blocking Na K ATPase channels thus increasing the inward
Na current. This increases the Na Ca exchanger current increasing
intracellular Ca and improving excitation-contraction coupling and cardia






Increased intracellular Na and Ca and decreased K creates resting
membrane instability. This leads to automaticity and the lengthening of the action
potential duration with DAD and EAD formation (Dawson & Buckley, 2007)
Hypomagnesaemia has been recognized as a precipitating factor for digoxin
toxicity even in normal therapeutic ranges (Cohen & Kitzes, 1983). As noted
previously magnesium suppressed EAD and DAD at higher levels (See 4
above). Magnesium enhances I currents at negative voltages thus suppressing
automaticity in ventricular tissue (see 2)c)iv) above)
Magnesium plays a vital role in many intracellular functions. It modulates cardiac
ion channels via direct or indirect mechanisms. Mg regulatesATPase activating
membrane electrogenic pumps. It inhibits L-Type Ca channels and Ca release
from the SR. There is only a weak inhibition of T-Type Ca channels. Magnesium
causes inward rectification in I channels by pore block. The delayed I channels
are blocked at positive voltages but enhanced at negative voltages.
Ischeamia sets up a chain reaction altering ionic currents and producing the
substrate for arrhythmias. Automaticity, triggered activity and reenty
mechanisms occur due to ion current shifts. Magnesium has been shown to
block triggered activity – the primary cause of TdP andAF. It provides rate control
inAF and stops certain SVTs. In a meta-analysis of Mg use inAF it provided rate
control and rhythm control but both with wide confidence intervals. It suppressed
arrhythmias from digitalis toxicity through the Na K ATPase pump
enhancement. Magnesium's role in intracellular management is well established
in animal and human tissue laboratory studies. There is sparse clinical trial
evidence to support its routine primary use except in TdP. As more evidence of
magnesium's role in intracellular control is discovered we may see an increased
use either alone or in conjunction with other antiarrhythmics.
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